Basit öğe kaydını göster

dc.contributor.authorAYDOGAN, U
dc.contributor.authorOMEROGLU, Rukiye Nurten
dc.contributor.authorERTUGRUL, T
dc.contributor.authorTANMAN, B
dc.contributor.authorDINDAR, A
dc.contributor.authorCANTEZ, T
dc.date.accessioned2021-12-10T11:35:38Z
dc.date.available2021-12-10T11:35:38Z
dc.date.issued1992
dc.identifier.citationAYDOGAN U., CANTEZ T., DINDAR A., TANMAN B., ERTUGRUL T., OMEROGLU R. N. , "FIBRINOLYTIC THERAPY FOR FEMORAL ARTERIAL THROMBOSIS AFTER CARDIAC-CATHETERIZATION IN INFANTS AND CHILDREN", JOURNAL OF INVASIVE CARDIOLOGY, cilt.4, sa.9, ss.445-447, 1992
dc.identifier.issn1042-3931
dc.identifier.otherav_87abccae-eba2-4130-b155-8c3a97518617
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/172201
dc.description.abstractData on 149 children who underwent retrograde arterial catheterization were studied to assess the frequency of femoral arterial thrombosis, and the safety and efficacy of systemic fibrinolytic therapy for this complication. Fourteen patients (9.4%) who had a pulseless extremity four hours after the catheterization were assumed to have femoral artery thrombosis. Thrombosis complicated patients were divided into two groups. The first group (7 patients) received only heparin treatment, and then 6 of them underwent thrombectomy. In the second group, 2 patients received only streptokinase, and 5 patients received streptokinase after heparin administration. Only 1 patient (who received streptokinase 1000 U/kg/hour after 1000 U/kg bolus) underwent thrombectomy in this group. The success rate was 86% (p<0.05). In another patient who had undergone sclerozan therapy for hemangioma and received streptokinase in the dose the previous patient received, symptoms of intracranial bleeding were noted at the sixth hour of therapy with reversal of the femoral pulses. These findings show that streptokinase is an alternative therapy to thrombectomy in the treatment of catheterization complicated arterial thrombosis. However, it is not as safe as previously mentioned, and must be avoided for the patients who may be at risk of arteriovenous malformation.
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectCARDIAC ve CARDIOVASCULAR SİSTEMLER
dc.subjectKlinik Tıp
dc.subjectTıp
dc.subjectHealth Sciences
dc.subjectCardiology and Cardiovascular Medicine
dc.subjectKardiyoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.titleFIBRINOLYTIC THERAPY FOR FEMORAL ARTERIAL THROMBOSIS AFTER CARDIAC-CATHETERIZATION IN INFANTS AND CHILDREN
dc.typeMakale
dc.relation.journalJOURNAL OF INVASIVE CARDIOLOGY
dc.contributor.department, ,
dc.identifier.volume4
dc.identifier.issue9
dc.identifier.startpage445
dc.identifier.endpage447
dc.contributor.firstauthorID2639368


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster